Ajax Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Phase 1
Recruiting
- Conditions
- Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPMFPPV-MFPost-Essential Thrombocythemia MyelofibrosisPET-MF
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Ajax Therapeutics, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT06343805
- Locations
- 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Moffitt Cancer Cancer Center, Tampa, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
News
No news found